Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

Clinical trial NCT07139509 · RECRUITING

Trial details

NCT number: NCT07139509
Sponsor: Xi'an No.3 Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory Multiple Myeloma(MM)

Start date: 2024-10-03
Primary completion: 2028-07-30
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.